While immunomodulators (such as IL-6 inhibitors or tumor necrosis factor alpha (TNF-alpha) blockers) show promise in other inflammatory conditions, their use in severe dengue remains investigational, with limited preliminary data and concern about potential hemorrhagic complications. This evidence concerns the gene IL6 and dengue disease.